losartan and s 1033

losartan has been researched along with s 1033 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Bahabadi, M; Goudarzi, F; Hajilooi, M; Hashemnia, M; Hedayatyanfard, K; Karimi, J; Khanjarsim, V; Kheiripour, N; Khodadadi, I; Mohammadalipour, A; Sheikh, N; Solgi, G1

Reviews

2 review(s) available for losartan and s 1033

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022

Other Studies

1 other study(ies) available for losartan and s 1033

ArticleYear
Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl
    Drug and chemical toxicology, 2020, Volume: 43, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Carbon Tetrachloride; Drug Therapy, Combination; Liver Cirrhosis; Losartan; Male; Oxidative Stress; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Transforming Growth Factor beta1; Weight Gain

2020